Abstract
The effects of the CCKB-receptor agonist pentagastrin, a synthetic analogue of the cholecystokinin tetrapeptide (CCK-4), were studied in seven patients suffering from obsessive compulsive disorder (OCD) and seven healthy controls. All subjects were challenged with an IV dose of 0.6 µg/kg pentagastrin or placebo under double blind placebo controlled conditions, on two separate occasions, with a minimum interval of 1 week. Six (86%) out of seven OCD patients experienced a panic-like reaction after pentagastrin administration, against only two (29%) in the control group. These differences failed to reach statistical significance, probably due to the small sample size. No increases were observed in obsessions or compulsive behaviors as assessed with the Yale-Brown Obsessive Compulsive Challenge Scale, neither in the pentagastrin, nor in the placebo condition. These findings suggest that pentagastrin has panic-inducing properties in OCD patients, without affecting the core symptoms. The panic-inducing properties of pentagastrin are not specific for panic disorder patients, which might be indicative of a common neurobiological dysfunction in panic disorder and OCD at the level of CCK-B receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abelson JL, Nesse RM (1990) Cholecystokinin-4 and panic. Arch Gen Psychiatry 47:395
Abelson JL, Nesse RM (1994) Pentagastrin infusions in patients with panic disorder I. Symptoms and cardiovascular responses. Biol Psychiatry 36:73–83
Abelson JL, Nesse RM, Vinik AI (1994) Pentagastrine infusions in patients with panic disorder II. Neuroendocrinology. Biol Psychiatry 36:84–96
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th rev. American Psychiatric Press, Washington, DC
Bastani B, Nash F, Meltzer HY (1990) Prolactin and cortisol responses to MK-212 a serotonin agonist, in obsessive-compulsive disorder. Arch Gen Psychiatry 47:833–839
Bradwejn J, Koszycki D, Meterissian G (1990) Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83–85
Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 48:603–610
Charney DS, Heninger GR, Breier A (1984) Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:751–763
Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR (1988) Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan andm-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 45:177–185
Cowley DS, Hyde TS, Dager SR, Dunner DL (1987): Lactate infusion: the role of baseline anxiety. Psychiatry Res 21:169–179
de Montigny C (1989) Cholecystokinin tetrapeptide induces paniclike attacks in healthy volunteers. Arch Gen Psychiatry 46:511–517
Den Boer JA, Westenberg HGM, Klompmakers AA, van Lint LEM (1989) Behavioral biochemical and neuroendocrine concomitants of lactate-induced panic anxiety. Biol Psychiatry 26:612–622
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989) The Yale-Brown obsessive compulsive scale I. Development, use, and reliability. Arch Gen Psychiatry 46:1006–1011
Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GR (1995)m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry 38:138–149
Gorman JM, Liebowitz MR, Fyer AJ, Dillon D, Davies SO, Stein J, Klein DF (1985) Lactate infusions in obsessive-compulsive disorder. Am J Psychiatry 142:864–866
Hollander E, Decaria C, Nitescu A, Cooper T, Stover B, Gully R, Klein DF, Liebowitz MR (1991) Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. Psychiatry Res 37:161–177
Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, Liebowitz MR (1992) Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oralm-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 49:21–28
Koszycki D, Cox BJ, Bradwejn J (1993) Anxiety sensitivity and response to cholecystokinin in healthy volunteers. Am J Psychiatry 150:1881–1883
Lee MA, Cameron OG, Gurguis GNM, Glitz D, Smith CB, Hariharan M, Abelson JL, Curtis GC (1990) Alpha2-adrenoreceptor status in obsessive-compulsive disorder. Biol Psychiatry 27:1083–1093
Lesch KP, Hoh A, Disselkamp-Tietze J, Wiesmann M, Osterheider M, Schulte HM (1991) 5-Hydroxytryptamine1a receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls. Arch Gen Psychiatry 48:540–547
Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G (1985) Lactate provocation of panic attacks. II Biochemical and physiological findings. Arch Gen Psychiatry 42:709–719
McBride PA, DeMeo MD, Sweeney JA, Halper J, Mann JJ, Shear MK (1992) Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonistdl-fenfluramine in adults with obsessive-compulsive disorder. Biol Psychiatry 31:19–34
McNair DM, Lorr M, Droppelman LF (1971) Manual for the Profile of Mood States. Educational and Industrial Testing Service, San Diego, Calif.
Nair NP, Lal S, Thavundayil JX, Etienne P, Guyda H (1984) CCK-33 antagonizes apomorphine-induced growth hormone secretion and increases basal prolactin levels in man. Neuropeptides 4:281–291
Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, Murphy DL (1993) A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to iv mCPP. Biol Psychiatry 33:3–14
Rasmussen SA, Goodman WK, Woods SW, Heninger GR, Charney DS (1987) Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology 93:308–313
Thijssen JHH, Van den Berg JHM, Adlercreutz J (1980) Determination of cortisol in human plasma evaluation and comparison of seven assays. Clin Chem Acta 100:39–46
Van Megen HJGM, Westenberg HGM, Den Boer JA, Haigh JRM, Traub M (1994) Pentagastrine induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacol 114:449–455
Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL (1987) Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 44:946–951
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Leeuw, A.S., Westenberg, H.G.M., Den Boer, J.A. et al. Pentagastrin has panic-inducing properties in obsessive compulsive disorder. Psychopharmacology 126, 339–344 (1996). https://doi.org/10.1007/BF02247385
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02247385